Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1177/2040620718775629 http://scihub22266oqcxt.onion/10.1177/2040620718775629 C6041862!6041862!30013765     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Ther+Adv+Hematol 2018 ; 9 (7): 175-90 Nephropedia Template TP {{tp|p=30013765|t=2018. Update on the role of lenalidomide in patients with multiple myeloma |pdf=|usr=}}{{30013765}} gab.com Text Update on the role of lenalidomide in patients with multiple myeloma JO: Ther Adv Hematol http://www.kidney.de/pget.php?&tw=1&pmid=30013765 #FOAvip Lenalidomide is a derivative of thalidomide and belongs to the class of drugs known as the immunomodulatory drugs (IMiDs). The IMiDs have played a large role in improving the survival outcomes of patients with multiple myeloma. In particular, lenalidomide is currently standard of care in the newly diagnosed setting, in the maintenance setting post-autologous stem cell transplant, as well as in the relapsed/refractory setting. While the combination of lenalidomide and various proteasome inhibitors has proven particularly effective, there are emerging data demonstrating the effectiveness of lenalidomide in combination with other important classes of drugs including the monoclonal antibodies. Recent studies have provided insight into the molecular target of lenalidomide and the other IMiDs, although there is still much to be learned regarding the mechanisms by which lenalidomide affects the myeloma cell and the immune system. Here we review the molecular mechanisms of action, side effects, and the results of the clinical trials which have led to the widespread incorporation of lenalidomide into the myeloma therapeutic armamentarium. Twit Text FOAVip Update on the role of lenalidomide in patients with multiple myeloma ????Ther Adv Hematol http://www.kidney.de/pget.php?&tw=1&pmid=30013765 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=30013765 #FOAvip English Wikipedia <ref>{{Cite pmid|30013765}}</ref> Update on the role of lenalidomide in patients with multiple myeloma #MMPMID30013765 Holstein SA; Suman VJ; McCarthy PL Ther Adv Hematol 2018[Jul]; 9 (7): 175-90 PMID30013765show ga Lenalidomide is a derivative of thalidomide and belongs to the class of drugs known as the immunomodulatory drugs (IMiDs). The IMiDs have played a large role in improving the survival outcomes of patients with multiple myeloma. In particular, lenalidomide is currently standard of care in the newly diagnosed setting, in the maintenance setting post-autologous stem cell transplant, as well as in the relapsed/refractory setting. While the combination of lenalidomide and various proteasome inhibitors has proven particularly effective, there are emerging data demonstrating the effectiveness of lenalidomide in combination with other important classes of drugs including the monoclonal antibodies. Recent studies have provided insight into the molecular target of lenalidomide and the other IMiDs, although there is still much to be learned regarding the mechanisms by which lenalidomide affects the myeloma cell and the immune system. Here we review the molecular mechanisms of action, side effects, and the results of the clinical trials which have led to the widespread incorporation of lenalidomide into the myeloma therapeutic armamentarium. äUpdate on the role of lenalidomide in patients with multiple myeloma (epmc).pdf DeepDyve Pubget Overpricing